Antagonism of in vivo and ex vivo response to endotoxin by E5564, an synthetic lipid A analogue

Journal of Endotoxin Research

Volumn 8, Issue 6, 2002, Pages 483-488

  Rossignol, Daniel P ^a   Lynn, Melvyn ^a  

^a EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

E 5564; ENDOTOXIN; LATAMOXEF; LIPID A DERIVATIVE; UNCLASSIFIED DRUG;

BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; ENDOTOXEMIA; FEMALE; HUMAN; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MALE; PHARMACODYNAMICS; REVIEW;

ANIMALS; CELL CULTURE TECHNIQUES; CYTOKINES; DISEASE MODELS, ANIMAL; HALF-LIFE; HUMANS; LIPID A; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE;

ANIMALIA; BACTERIA (MICROORGANISMS); NEGIBACTERIA;

EID: 0036954040     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1179/096805102125001127     Document Type: Review

References (12)

1. Opal SM, Scannon PJ, Vincent JL et al. Relationship between plasma levels of lipoposaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999; 180: 1584-1589.
2. Martinez-Pellus AE, Merino P, Bru M et al. Endogenous endotoxemia of intestinal origin during cardiopulmonary bypass. Role of type of flow and protective effect of selective digestive decontamination [see comments]. Intensive Care Med 1997; 23: 1251-1257.
3. Sugita T, Watarida S, Katsuyama K et al. Endotoxemia after elective surgery for abdominal aortic aneurysm and the effect of early oral feeding. J Cardiovasc Surg (Torino) 1998; 39: 547-549.
4. Christ WJ, Asano O, Robidoux ALC et al. E5531, a pure endotoxin antagonist of high potency. Science 1995; 268: 80-83.
5. Rossignol Dp, Christ WJ, Hawkins LD et al. Synthetic endotoxin antagonists. In: Morrison DC. (ed) Endotoxin in Health and Disease. New York: Marcel Dekker, 1999; 699-717.
6. Rose JR, Christ WJ, Bristol JR, Kawata T, Rossignol DP. Agonistic and antagonistic activities of bacterially derived Rhodobacter sphaeroides lipid: A comparison with activities of synthetic material of the proposed structure and analogs. Infect Immun 1995; 63: 833-839.
7. Rose JR, Mullarkey MA, Christ WJ et al. Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins. Antimicrob Agents Chemother 2000; 44: 504-510.
8. Bunnell E, Lynn M, Habet K et al. A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia. Crit Care Med 2000; 28: 2731-2720.
9. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999; 274: 10689-10692.
10. Nau GJ, Richmond JF, Schlesinger A, Jennings EG, Lander ES, Young RA. Human macrophage activation programs induced by bacterial pathogens. Proc Natl Acad Sci USA 2002; 99: 1503-1508.
11. Morrison DC, Bucklin SE. Evidence for antibiotic-mediated endotoxin release as a contributing factor to lethality in experimental Gram-negative sepsis. Scand J Infect Dis Suppl 1996; 101: 3-8.
12. Wasan KM, Strobel FW, Parrott SC et al. Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels. Antimicrob Agents Chemother 1999; 43: 2562-2564.